Lunai Bioworks (2Q5) Stock Price & Analysis

2Q5 Stock Chart & Stats

€0.82€0.00(0.00%)

At close: Nov 02 5:30 PM GMT+1

Day’s Range: EUR 0.82 - EUR 0.82
52-Week Range: EUR 0.82 - EUR 0.82
Previous Close: EUR 0.82
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 741.82K
Enterprise Value: EUR 16.39T
Total Cash (Recent Filing): EUR 1.71B
Total Debt (Recent Filing): EUR 1.34B
Price to Earnings (P/E): ―
Beta: 1.47
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Lunai Bioworks News

Lunai Bioworks Voluntarily Withdraws From Nasdaq Listing

Lunai Bioworks ( ($LNAI) ) has shared an update. On October 21, 2026, Lunai Bioworks received notice from Nasdaq that it no longer met the minimum stockholders’ equity requirement, after

1w ago8K LNAI

Lunai Bioworks Seeks Nasdaq Trading Suspension Amid Probe

Lunai Bioworks ( ($LNAI) ) has issued an update. On October 9, 2026, Lunai Bioworks asked Nasdaq to immediately suspend trading in its common stock while authorities review trading records

3w ago8K LNAI

Lunai Bioworks Delays Annual SEC Filing Briefly

Lunai Bioworks ( ($LNAI) ) has released a notification of late filing. Lunai Bioworks Inc. has filed a Form 12b-25, signaling a delayed submission of its Form 10-K (Yearly Report)

1M agoLNAI 2Q5

Lunai Bioworks expands Parkinson’s platform through agreement with Tanaist

Lunai Bioworks (LNAI) announced an exclusive worldwide license and collaboration agreement with Tanaist that adds human cellular phenotyping to Lunai’s Parkinson’s disease discovery and validation platform. The collaboration is designed

1M agoLNAI 2Q5

Lunai Bioworks Pursues Legal Action Over Alleged Manipulation

An announcement from Lunai Bioworks ( ($LNAI) ) is now available. In April 2026, Lunai Bioworks secured its first revenue-generating, multi-year U.S. defense collaboration via BioSymetrics to deploy its AI-enabled

4M ago8K LNAI

Lunai Bioworks Regains Nasdaq Compliance, Enters Monitoring Period

The latest update is out from Lunai Bioworks ( ($LNAI) ). On June 11, 2026, Lunai Bioworks, Inc. disclosed that Nasdaq had confirmed the company regained compliance with the exchange’s

4M ago8K LNAI

Lunai Bioworks and BrainStorm launch foundation for neurological diseases

Lunai Bioworks’ (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic targets for neurological diseases.

5M agoBCLI LNAI

Lunai Bioworks Inc. trading halted, news pending

19:50 EDT Lunai Bioworks (LNAI) Inc. trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

5M agoLNAI 2Q50

Lunai Bioworks Announces 1-for-8 Reverse Stock Split

The latest announcement is out from Lunai Bioworks ( ($LNAI) ). Lunai Bioworks, Inc. announced on May 20, 2026, that it will implement a 1-for-8 reverse stock split of its

5M ago8K LNAI

Lunai Bioworks announces reverse stock split

Lunai Bioworks (LNAI) announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-8. The

5M agoLNAI 2Q50

Lunai Bioworks Shareholders Approve Flexible Reverse Stock Split

Lunai Bioworks ( ($LNAI) ) just unveiled an update. On May 8, 2026, Lunai Bioworks stockholders approved an amendment to the company’s Certificate of Incorporation to authorize a reverse stock

5M ago8K LNAI

Lunai Bioworks Completes Merger and Issues Preferred Stock

Lunai Bioworks ( ($LNAI) ) has shared an update. On May 1, 2026, Lunai Bioworks completed a triangular merger in which Neurobridge IP Holdings merged into Lunai Bioworks IP, making

6M ago8K LNAI

Lunai Bioworks Delays Special Stockholder Meeting to May

Lunai Bioworks ( ($LNAI) ) has provided an announcement. On April 28, 2026, Lunai Bioworks announced it had postponed its Special Meeting of Stockholders from May 4 to May 8,

6M ago8K LNAI

Lunai Bioworks Expands CNS Portfolio With $20M Acquisition

Lunai Bioworks ( ($LNAI) ) just unveiled an update. On March 24, 2026, Lunai Bioworks, Inc. entered into debt exchange agreements with three holders of its secured promissory notes to

7M ago8K LNAI

2Q5 FAQ

What was Lunai Bioworks’s price range in the past 12 months?

Lunai Bioworks lowest stock price was €0.82 and its highest was €0.82 in the past 12 months.

What is Lunai Bioworks’s market cap?

Lunai Bioworks’s market cap is €741.82K.

When is Lunai Bioworks’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Lunai Bioworks’s earnings last quarter?

Lunai Bioworks released its earnings results on May 15, 2023. The company reported -€0.067 earnings per share for the quarter.

Is Lunai Bioworks overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Lunai Bioworks pay dividends?

Lunai Bioworks does not currently pay dividends.

What is Lunai Bioworks’s EPS estimate?

Lunai Bioworks’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lunai Bioworks have?

Lunai Bioworks has 5,034,452 shares outstanding.

What happened to Lunai Bioworks’s price movement after its last earnings report?

Lunai Bioworks reported an EPS of -€0.067 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Lunai Bioworks?

Currently, no hedge funds are holding shares in DE:2Q5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lunai Bioworks

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Lunai Bioworks (2Q5) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	7	1	6
Technical Analysis	1	1	0
Moving Averages	6	0	6

Technical Analysis >

Similar Stocks

Stocks similar to DE:2Q5
Company	Price & Change	Follow
DAREDaré Bioscience
AKTXAkari Therapeutics
CLGNCollplant Holdings
NRSNNeurosense Therapeutics Ltd.

Compare DE:2Q5 Stocks >

Ownership Overview

1.04% Mutual Funds
1.37% Other Institutional Investors
96.59% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft